Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.47 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.45 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902205 | 0.83 | HSD17B10 (0.39) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL3893214 | 0.82 | CA1 (0.57) | ALDH1A1CA2KMT2AGAAMAPT | |
| SCHEMBL3835013 | 0.82 | CA2 (0.68) | ALDH1A1CA2CA5AKMT2APLK1 | |
| SCHEMBL3896906 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL11245631 | 0.81 | TGM2 (0.54) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL3896251 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL725810 | 0.78 | ALDH1A1 (0.75) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| Potassium Ion SCHEMBL11594818 | 0.78 | CA1 (0.57) | ALDH1A1CA2KMT2AGAAMAPT | |
| SCHEMBL4523480 | 0.78 | ALDH1A1 (0.52) | ALDH1A1CYP3A4CYP2D6CYP2C9HPGD | |
| SCHEMBL4528454 | 0.77 | SMN1; SMN2 (0.62) | ALDH1A1TP53TSHRHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | disclosed |
| EP-0765357-B9 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-0927217-B1 | ANGIOGENIC INHIBITORY COMPOUNDS | STARPHARMA PTY LTD (AU) | 2006-05-03 | — | — | EP | disclosed |
| EP-0765357-B8 | ANTIVIRAL DENDRIMERS | STARPHARMA PTY LTD (AU) | 2006-03-08 | — | — | EP | disclosed |
| EP-0765357-B1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 2005-12-14 | — | — | EP | disclosed |
| US-6740635-B2 | AIDS THERAPY, RESPIRATORY SYNCYTIAL VIRUS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2004-05-25 | — | — | US | disclosed |
| EP-1113805-A4 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LTD (AU) | 2004-05-19 | — | — | EP | disclosed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | disclosed |
| EP-1113806-A4 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LTD (AU) | 2003-06-25 | — | — | EP | disclosed |
| US-6190650-B1 | FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 2001-02-20 | — | — | US | disclosed |
| WO-2000015240-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015239-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| EP-0928306-A1 | ANTIVIRAL LINEAR POLYMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927217-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998003573-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003572-A1 | ANTIVIRAL LINEAR POLYMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
| EP-0765357-A4 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RES INST LTD (AU) | 1997-07-30 | — | — | EP | disclosed |
| EP-0765357-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034595-A1 | ANTIVIRAL DENDRIMERS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | CA2 1974/4885CA1 2006/4885CA4 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.